Cristina Gasparetto, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address gaspa001@mc.duke.edu

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Education and Training

  • Fellow in Hematology/Oncology, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.D., Sapienza University of Rome (Italy), 1986

Grants

Publications

Maung, Ko K., Benny J. Chen, Ian Barak, Zhiguo Li, David A. Rizzieri, Cristina Gasparetto, Keith M. Sullivan, et al. “Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.” Bone Marrow Transplant, July 5, 2020. https://doi.org/10.1038/s41409-020-0991-5.

PMID
32624583
Full Text

Jagannath, Sundar, Robert M. Rifkin, Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Howard R. Terebelo, et al. “Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.” Clin Lymphoma Myeloma Leuk 20, no. 5 (May 2020): 272–76. https://doi.org/10.1016/j.clml.2019.10.002.

PMID
32144027
Full Text

Gavriatopoulou, Maria, Ajai Chari, Christine Chen, Nizar Bahlis, Dan T. Vogl, Andrzej Jakubowiak, David Dingli, et al. “Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.” Leukemia, February 24, 2020. https://doi.org/10.1038/s41375-020-0756-6.

PMID
32094461
Full Text

Chari, Ajai, Robert F. Cornell, Cristina Gasparetto, Chatchada Karanes, Jeffrey V. Matous, Ruben Niesvizky, Matthew Lunning, et al. “Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.” Hematol Oncol, February 13, 2020. https://doi.org/10.1002/hon.2723.

PMID
32053229
Full Text

Ailawadhi, Sikander, Sundar Jagannath, Mohit Narang, Robert M. Rifkin, Howard R. Terebelo, Kathleen Toomey, Brian G. M. Durie, et al. “Connect MM Registry as a national reference for United States multiple myeloma patients.” Cancer Med 9, no. 1 (January 2020): 35–42. https://doi.org/10.1002/cam4.2656.

PMID
31701679
Full Text

Terebelo, Howard R., Rafat Abonour, Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Sundar Jagannath, et al. “Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry.” Br J Haematol 187, no. 5 (December 2019): 602–14. https://doi.org/10.1111/bjh.16139.

PMID
31382320
Full Text

Stadtmauer, Edward A., Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.” J Clin Oncol 37, no. 7 (March 1, 2019): 589–97. https://doi.org/10.1200/JCO.18.00685.

PMID
30653422
Full Text

Zheng, Jing, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick, Jagadish Kummetha Venkta, Cleopatra Kozlowski, et al. “Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.” Cancer Lett 440–441 (January 2019): 1–10. https://doi.org/10.1016/j.canlet.2018.10.003.

PMID
30312729
Full Text

Bahlis, Nizar J., Heather Sutherland, Darrell White, Michael Sebag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, et al. “Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.” Blood 132, no. 24 (December 13, 2018): 2546–54. https://doi.org/10.1182/blood-2018-06-858852.

PMID
30352784
Full Text

Pages